Hypolidemic therapy today. New challenges and opportunities of statines
Prevention of fatal complications in patients with high cardiovascular risk means achieving target blood cholesterol and its fraction in low-density lipoprotein levels, which level depends on the cardiovascular risk (CVR) degree and is determined by the guidelines of the European Cardiology Society...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-04-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2355 |
| _version_ | 1797841355333959680 |
|---|---|
| author | V. P. Mikhin V. V. Vorotyntseva Yu. A. Zhilyaeva M. A. Chernyatina N. I. Gromnatsky O. A. Sushenya |
| author_facet | V. P. Mikhin V. V. Vorotyntseva Yu. A. Zhilyaeva M. A. Chernyatina N. I. Gromnatsky O. A. Sushenya |
| author_sort | V. P. Mikhin |
| collection | DOAJ |
| description | Prevention of fatal complications in patients with high cardiovascular risk means achieving target blood cholesterol and its fraction in low-density lipoprotein levels, which level depends on the cardiovascular risk (CVR) degree and is determined by the guidelines of the European Cardiology Society (2016) and the Russian National Atherosclerosis Society (2017). When choosing statins for lipid-lowering therapy, one should be guided by the hepatic metabolism nature, hypolipidemic activity, and the pleiotropic profiles of the drug. |
| first_indexed | 2024-04-09T16:29:39Z |
| format | Article |
| id | doaj.art-6a1ed642e88a4cf78bd81b3eb3b7f535 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:29:39Z |
| publishDate | 2018-04-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-6a1ed642e88a4cf78bd81b3eb3b7f5352023-04-23T06:57:08ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-04-0105485310.21518/2079-701X-2018-5-48-532331Hypolidemic therapy today. New challenges and opportunities of statinesV. P. Mikhin0V. V. Vorotyntseva1Yu. A. Zhilyaeva2M. A. Chernyatina3N. I. Gromnatsky4O. A. Sushenya5Kursk State Medical UniversityKursk State Medical UniversityKursk State Medical UniversityKursk State Medical UniversityKursk State Medical UniversityKursk State Medical UniversityPrevention of fatal complications in patients with high cardiovascular risk means achieving target blood cholesterol and its fraction in low-density lipoprotein levels, which level depends on the cardiovascular risk (CVR) degree and is determined by the guidelines of the European Cardiology Society (2016) and the Russian National Atherosclerosis Society (2017). When choosing statins for lipid-lowering therapy, one should be guided by the hepatic metabolism nature, hypolipidemic activity, and the pleiotropic profiles of the drug.https://www.med-sovet.pro/jour/article/view/2355atherosclerosischolesterolstatinsrosuvastatin |
| spellingShingle | V. P. Mikhin V. V. Vorotyntseva Yu. A. Zhilyaeva M. A. Chernyatina N. I. Gromnatsky O. A. Sushenya Hypolidemic therapy today. New challenges and opportunities of statines Медицинский совет atherosclerosis cholesterol statins rosuvastatin |
| title | Hypolidemic therapy today. New challenges and opportunities of statines |
| title_full | Hypolidemic therapy today. New challenges and opportunities of statines |
| title_fullStr | Hypolidemic therapy today. New challenges and opportunities of statines |
| title_full_unstemmed | Hypolidemic therapy today. New challenges and opportunities of statines |
| title_short | Hypolidemic therapy today. New challenges and opportunities of statines |
| title_sort | hypolidemic therapy today new challenges and opportunities of statines |
| topic | atherosclerosis cholesterol statins rosuvastatin |
| url | https://www.med-sovet.pro/jour/article/view/2355 |
| work_keys_str_mv | AT vpmikhin hypolidemictherapytodaynewchallengesandopportunitiesofstatines AT vvvorotyntseva hypolidemictherapytodaynewchallengesandopportunitiesofstatines AT yuazhilyaeva hypolidemictherapytodaynewchallengesandopportunitiesofstatines AT machernyatina hypolidemictherapytodaynewchallengesandopportunitiesofstatines AT nigromnatsky hypolidemictherapytodaynewchallengesandopportunitiesofstatines AT oasushenya hypolidemictherapytodaynewchallengesandopportunitiesofstatines |